On September 3, 2026, KALA BIO, Inc. entered into an Exclusive Distribution and Reseller Agreement with Virotek, Inc., appointing Kala as the sole exclusive distributor and reseller of a genetic testing and screening program for ophthalmology in the United States. The agreement has an initial term of five years, contingent on Kala achieving specific milestones by September 3, 2027; failure to meet these milestones converts the appointment from exclusive to non-exclusive. Net profits are split equally between the parties after Virotek recovers its cost of goods sold. KALA BIO, Inc. operates in the biotechnology industry, focusing on developing therapies for rare eye diseases.

KALA BIO, Inc. received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its common stock has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days ending August 26, 2026. Because KALA BIO effected a 1-for-50 reverse stock split on May 11, 2026, it is ineligible for the standard 180-day compliance period. The company intends to request a hearing before the Nasdaq Hearings Panel to appeal this determination, which would stay any suspension or delisting action pending the outcome. There is no assurance that the request will be granted or that the company can regain compliance. KALA BIO operates in the biotechnology industry, focusing on drug discovery and development.

Kala Bio, Inc. filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933 regarding an offering of securities under its existing Form S-3 registration statement. This 8-K filing provides the legal opinion from Haynes and Boone, LLP concerning the validity of the securities being offered. Kala Bio, Inc. is a biotechnology company.